Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

4D Molecular Therapeutics Inc (FDMT)

4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 181,504
  • Shares Outstanding, K 46,302
  • Annual Sales, $ 40 K
  • Annual Income, $ -160,870 K
  • EBIT $ -168 M
  • EBITDA $ -171 M
  • 60-Month Beta 2.83
  • Price/Sales 4,692.77
  • Price/Cash Flow N/A
  • Price/Book 0.34

Options Overview Details

View History
  • Implied Volatility 332.10% ( +128.94%)
  • Historical Volatility 80.25%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 332.10% on 03/21/25
  • IV Low 21.33% on 08/12/24
  • Put/Call Vol Ratio 0.32
  • Today's Volume 455
  • Volume Avg (30-Day) 91
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 5,153
  • Open Int (30-Day) 4,667

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.84
  • Number of Estimates 4
  • High Estimate -0.75
  • Low Estimate -0.92
  • Prior Year -0.66
  • Growth Rate Est. (year over year) -27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.58 +9.50%
on 03/21/25
4.86 -19.42%
on 02/27/25
-0.72 (-15.52%)
since 02/21/25
3-Month
3.58 +9.50%
on 03/21/25
6.91 -43.27%
on 02/06/25
-2.39 (-37.88%)
since 12/20/24
52-Week
3.58 +9.50%
on 03/21/25
36.25 -89.19%
on 03/27/24
-29.88 (-88.40%)
since 03/21/24

Most Recent Stories

More News
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

FDMT : 3.92 (+4.53%)
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

FDMT : 3.92 (+4.53%)
4DMT to Participate in Upcoming Investor Conferences

FDMT : 3.92 (+4.53%)
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

FDMT : 3.92 (+4.53%)
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

FDMT : 3.92 (+4.53%)
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

FDMT : 3.92 (+4.53%)
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path

FDMT : 3.92 (+4.53%)
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

FDMT : 3.92 (+4.53%)
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

FDMT : 3.92 (+4.53%)
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

FDMT : 3.92 (+4.53%)

Business Summary

4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas....

See More

Key Turning Points

3rd Resistance Point 4.41
2nd Resistance Point 4.17
1st Resistance Point 4.05
Last Price 3.92
1st Support Level 3.69
2nd Support Level 3.45
3rd Support Level 3.33

See More

52-Week High 36.25
Fibonacci 61.8% 23.77
Fibonacci 50% 19.92
Fibonacci 38.2% 16.06
Last Price 3.92
52-Week Low 3.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar